| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ACAD | ACAD | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ACAD | ACAD | Shares | USD | XNGS |
Acadia Pharmaceuticals Inc. focuses on developing treatments for underserved neurological disorders and rare diseases. Its clinical-stage programs primarily target Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with early-stage initiatives addressing other unmet patient needs. The company is also seeking approval for a treatment option for Rett syndrome in Europe.
No recent RNS announcements for ACAD across ACAD.
No recent RNS announcements for ACAD across ACAD.